Will Novo’s big thinking in obesity pay off?
Novo Nordisk has high hopes that obesity will become a major source of sales, and data on the company’s most promising projects are looming.
Acceleron’s post-Reblozyl plan comes together
Sotatercept’s win in pulmonary arterial hypertension positions Acceleron for a battle against the leaders in this crowded space.
FDA decision time looms for Gelesis
Gelesis’s weight-loss capsule only hit one of the two co-primary endpoints in its approval trial. Will the FDA be persuaded?